SG10201803178UA - Stable, aqueous antibody formulations - Google Patents
Stable, aqueous antibody formulationsInfo
- Publication number
- SG10201803178UA SG10201803178UA SG10201803178UA SG10201803178UA SG10201803178UA SG 10201803178U A SG10201803178U A SG 10201803178UA SG 10201803178U A SG10201803178U A SG 10201803178UA SG 10201803178U A SG10201803178U A SG 10201803178UA SG 10201803178U A SG10201803178U A SG 10201803178UA
- Authority
- SG
- Singapore
- Prior art keywords
- stable
- antibody formulations
- aqueous antibody
- aqueous
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361895143P | 2013-10-24 | 2013-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201803178UA true SG10201803178UA (en) | 2018-05-30 |
Family
ID=52993565
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603206UA SG11201603206UA (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
SG10201803178UA SG10201803178UA (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603206UA SG11201603206UA (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Country Status (23)
Country | Link |
---|---|
US (3) | US20150118249A1 (fr) |
EP (2) | EP3892288A1 (fr) |
JP (3) | JP6483673B2 (fr) |
KR (3) | KR20210041101A (fr) |
CN (3) | CN105611938A (fr) |
AU (3) | AU2014339984B2 (fr) |
BR (1) | BR112016008576B1 (fr) |
CA (1) | CA2926089C (fr) |
CY (1) | CY1125697T1 (fr) |
DK (1) | DK3060229T3 (fr) |
ES (1) | ES2893861T3 (fr) |
HK (1) | HK1221900A1 (fr) |
HR (1) | HRP20211371T1 (fr) |
HU (1) | HUE055919T2 (fr) |
LT (1) | LT3060229T (fr) |
MX (2) | MX2016004605A (fr) |
PL (1) | PL3060229T3 (fr) |
PT (1) | PT3060229T (fr) |
RS (1) | RS62419B1 (fr) |
RU (2) | RU2021137159A (fr) |
SG (2) | SG11201603206UA (fr) |
SI (1) | SI3060229T1 (fr) |
WO (1) | WO2015061584A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
AU2013256229A1 (en) * | 2012-05-03 | 2014-10-30 | Medimmune, Llc | Method for analyzing sample components |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
EP3892288A1 (fr) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Formulations d'anticorps aqueuses stables |
EP3116907A1 (fr) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anticorps anti-laminine4 spécifiques contre lg4 -5 |
JP6728053B2 (ja) | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗mcam抗体及び関連する使用方法 |
JP2018530540A (ja) * | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗mcam抗体の使用 |
JP2018535242A (ja) * | 2015-11-30 | 2018-11-29 | メディミューン,エルエルシー | 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比 |
CN109803640B (zh) * | 2016-08-10 | 2022-01-04 | 赛特瑞恩股份有限公司 | 稳定的液体抗流感病毒抗体医药调配物 |
AU2017345490B2 (en) * | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
EP3927729A4 (fr) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | Formulation d'anticorps thérapeutique |
TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
WO2021124793A1 (fr) * | 2019-12-16 | 2021-06-24 | ニプロ株式会社 | Agent inhibiteur d'agrégation, et composition médicale et dispositif médical le comprenant |
CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
KR20220152540A (ko) * | 2020-03-13 | 2022-11-16 | 삼성바이오에피스 주식회사 | 안정성이 증진된 액상 약제학적 조성물 |
CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业(上海)股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
CN116887860A (zh) * | 2020-12-17 | 2023-10-13 | 阿斯利康(瑞典)有限公司 | 抗il5r抗体配制品 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
KR100259828B1 (ko) * | 1995-09-11 | 2000-06-15 | 히라타 다다시 | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 |
BRPI0410658B8 (pt) * | 2003-05-26 | 2021-06-22 | In Baik Woo | seringa descartável |
DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
AU2008232902B2 (en) * | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
SG10201503254TA (en) | 2007-05-14 | 2015-06-29 | Medimmune Llc | Methods of reducing eosinophil levels |
JP5524967B2 (ja) * | 2008-09-19 | 2014-06-18 | エフ.ホフマン−ラ ロシュ アーゲー | 新規抗体処方物 |
SG174258A1 (en) * | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
SG175188A1 (en) * | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
JP6220789B2 (ja) * | 2011-10-18 | 2017-10-25 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤 |
WO2013062841A1 (fr) * | 2011-10-26 | 2013-05-02 | Bio-Rad Laboratories, Inc. | Élimination des agents virucides en chromatographie en mode mixte |
EP2771033A4 (fr) * | 2011-10-28 | 2016-02-17 | Integritybio Inc | Formulations protéiques contenant des acides aminés |
KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
LT3033101T (lt) * | 2013-08-12 | 2019-03-25 | Astrazeneca Ab | Astmos paūmejimo dažnio sumažinimo būdai naudojant benralizumabą |
AU2014306959B2 (en) * | 2013-08-12 | 2019-11-21 | Astrazeneca Ab | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
EP3892288A1 (fr) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Formulations d'anticorps aqueuses stables |
-
2014
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/fr active Pending
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Application Discontinuation
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active IP Right Grant
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 CN CN201480055263.0A patent/CN105611938A/zh active Pending
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/fr active Application Filing
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 MX MX2016004605A patent/MX2016004605A/es unknown
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active IP Right Grant
- 2014-10-23 CA CA2926089A patent/CA2926089C/fr active Active
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/fr active Active
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
- 2016-08-23 HK HK16110007.2A patent/HK1221900A1/zh unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US20190201535A1/en active Pending
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-08-30 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221900A1 (zh) | 穩定的水性抗體配製品 | |
ZA202005525B (en) | Antibody formulations | |
IL244712A0 (en) | Anti-pdl1 antibody compositions | |
IL240754A0 (en) | Low concentration antibody compositions | |
EP3065716C0 (fr) | Formulations | |
GB201319792D0 (en) | Formulations | |
DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
HK1214951A1 (zh) | 眼用製劑 | |
GB201411896D0 (en) | . | |
HK1217652A1 (zh) | 水性組合物 | |
EP3004265A4 (fr) | Composition aqueuse | |
HK1220366A1 (zh) | 蛋白製劑 | |
EP2952190A4 (fr) | Solution aqueuse stable | |
EP3057451A4 (fr) | Formulations spécifiques aux protéines | |
EP2952189A4 (fr) | Solution aqueuse limpide | |
EP2968383A4 (fr) | Formulations aqueuses concentrées d'azalide | |
GB201409791D0 (en) | . | |
GB201322661D0 (en) | . | |
GB201312935D0 (en) | T,b,s |